Interleukin-6 and Oxidative Stress in Plasma of Alloxan-Induced Diabetic Rabbits after Pioglitazone Treatment

REFERENCES

• Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., Quagliaro L., Ceriello A., Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Circulation 2002; 106: 2067–2072, Role of oxidative stress[PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Ogawa J., Takahashi S., Fujiwara T., Fukushige J., Hosokawa T., Izumi T., Kurakata S., Horikoshi H. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci 1999; 65: 1287–1296, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pickup J.C., Chusney G.D., Thomas S.M., Burt D. Plasma interleukin-6, tumor necrosis factor-α and blood cytokine production in type 2 diabetes. Life Sci 2000; 67: 291–300, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Stosic-Grujicic S.D., Miljkovic D.M., Cvetkovic I.D., Maksimovic-Ivanic D.D., Trajkovic V. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. J. Autoimmun 2004; 22: 267–276, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., Ishibashi M., Kubota T., Egashira K., Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126–32, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ghanim H., Garg R., Aljada A., Mohanty P., Kumbkarni Y., Assian E., Hamouda W., Dandona P. Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J. Clin. Endocrinol. Metab 2001; 86: 1306–1312, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dandona P. Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action. J. Clin. Endocrinol. Metab 2001; 86: 3250–3256, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nattrass M., Bailey C.J. New agents for type 2 diabetes. Res. Clin. Endocrinol. Metab 1999; 13: 309–329, Baillieres Best Pract[CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rahbar S., Natarajan R., Yerneni K., Scott S., Gonzales N., Nadler J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta 2000; 301: 65–77, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Iida K.T., Kawakami Y., Suzuki M., Shimano H., Toyoshima H., Sone H., Shimada K., Iwama Y., Watanabe Y., Mokuno H., Kamata K., Yamada N. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am. J. Physiol. Endocrinol. Metab 2003; 284: E1125–E1130, [CSA]
   PubMed Web of Science ®Google Scholar
• Ishida H., Takizawa M., Ozawa S., Nakamichi Y., Yamaguchi S., Katsuta H., Tanaka T., Maruyama M., Katahira H., Yoshimoto K., Itagaki E., Nagamatsu S. Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of β cell from oxidative stress. Metabolism 2004; 53: 488–494, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mizushige K., Tsuji T., Noma T. Pioglitazone: cardiovascular effects in prediabetic patients. Cardiovasc. Drug Rev 2002; 20: 329–340, [CSA]
   PubMed Web of Science ®Google Scholar
• Gumieniczek A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 2003; 74: 553–562, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A., Abreu-Gonzales P., Garcia M., Ferrer J., de la Rosa A., Vargas M., Reiter R.J. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 2004; 26: 89–93, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ito K., Shimada J., Kato D., Toda S., Takagi T., Naito Y., Yoshikawa T., Kitamura N. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, on lung ischemia-reperfusion in rats. Eur. J. Cardiothorac. Surg 2004; 25: 530–536, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem 1951; 193: 265–275, [CSA]
   PubMed Web of Science ®Google Scholar
• Kyaw A. A simple colorimetric method for ascorbic acid determination in blood plasma. Clin. Chim. Acta 1978; 86: 153–157, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Levine R.L., Garland D., Oliver C.N., Amici A., Climent J., Lenz A., Ahn B., Shaltiel S., Stadtman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods. Enzymol 1990; 186: 464–478, [CSA]
   PubMed Web of Science ®Google Scholar
• Dandona P., Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am. J. Cardiol 2002; 90: 27G–33G, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dandona P., Aljada A., Chaudhuri A. Vascular reactivity and thiazolidinediones. Am. J. Med 2003; 115: 81S–86S, [CROSSREF], [CSA]
   Web of Science ®Google Scholar
• Yatagai T., Nakamura T., Nagasaka S., Kusaka I., Ishikawa S., Yoshitaka A., Ishibashi S. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Res. Clin. Pract 2004; 63: 19–26, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pasceri V., Wu H.D., Willerson J.T., Yeh E.T.H. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 2000; 101: 235–238, [CSA]
   PubMed Web of Science ®Google Scholar
• Ogawa J., Takahashi S., Fujiwara T., Fukushige J., Hosokawa T., Izumi T., Kurakata S., Horikoshi H. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci 1999; 65: 1287–1296, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bánhegyi G., Braun L., Csala M., Puskás F., Mandl J. Ascorbate metabolism and its regulation in animals. Free Radic. Biol. Med 1997; 23: 793–803, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ananthan R., Baskar C., NarmathaBai V., Pari L., Latha M., Ramkumar K.M. Antidiabetic effect of Gymnema montanum leaves: effect on lipid peroxidation induced oxidative stress in experimental diabetes. Pharmacol. Res 2003; 48: 551–556, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Škrha J., Prázný M., Hilgertová J., Weiserová H. Serum α-tocopherol and ascorbic acid concentrations in type 1 and type 2 diabetic patients with and without angiopathy. Clin. Chim. Acta 2003; 329: 103–108, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Telci A., Çakatay U., Salman S., Satman I., Sivas A. Oxidative protein damage in early stage type 1 diabetic patients. Diabetes Res. Clin. Pract 2000; 50: 213–223, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Signorini A.M., Fondelli C., Renzoni E., Puccetti C., Gragnoli G., Giorgi G. Antioxidant effects of gliclazide, glibenclamide, and metformin in patients with type 2 diabetes mellitus. Curr. Ther. Res 2002; 63: 411–420, [CROSSREF], [CSA]
   Web of Science ®Google Scholar
• De Mattia G., Laurenti O., Fava D. Diabetic endothelial dysfunction. J. Diabetes Complications 2003; 17: 30–35, Effect of free radical scavenging in type 2 diabetic patients[CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mimič-Oka J., Simič T., Plješa M., Stupar N., Turkovič S. Oxidative modifications of plasma proteins in different stages of chronic renal failure. Facta Universitatis 2001; 8: 1–5, [CSA]
   Google Scholar
• Martín-Gallan P., Carrascosa A., Gussinyé M., Domínguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic. Biol. Med 2003; 34: 1563–1574, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Odetti P., Garibaldi S., Noberasco G., Aragno I., Valentini S., Traverso N., Marinari U.M. Levels of carbonyl groups in plasma proteins of type 2 diabetes mellitus. Acta Diabetol 1999; 36: 179–183, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar